NextGen Healthcare, Inc. recently announced that Pametto Retina Center (“Palmetto”) has adopted NextGen Revenue Cycle Management (RCM) Services. Palmetto, which is currently using NextGen Enterprise Practice Management (PM) and NextGen Enterprise electronic health record (EHR), has adopted NextGen RCM Services for six locations in South Carolina. With the addition of NextGen RCM Services, Palmetto will reap the benefits of the integrated platform backed by expert managed services focused on boosting cashflow while lowering administrative burden.
Notably, NextGen RCM Services aids practices in preventing denials, enhance speed of collections, increase net collections, and lower days in accounts receivable, thereby improving overall patient experience.
NextGen is a major player in the U.S. RCM market and this announcement is likely to strengthen its position further in the same.
More on the News
For a healthy and smooth flowing retina practice, timely reimbursement for medications and surgeries is crucial. On the back of the expansion of Palmetto’s collaboration with NextGen, the former will be able to receive an end-to-end solution for its team.
Per management, with the continued evolution of the market, there is a higher demand for the combination of well-integrated clinical and financial workflows coupled with managed services.
This partnership will allow NextGen to cater to the needs of the changing healthcare environment and enhance Palmetto’s financial strength.
Market Prospects
Per a report by Grand View Research, the global revenue cycle management market was worth $261.8 billion in 2020 and is projected to witness a CAGR of 11.5% from 2021 to 2028. Growing need for optimization of organizational workflow, and increase in innovation in synchronized management software and systems are expected to drive market growth. Hence, the announcement is well-timed for NextGen.
Recent Developments
In May, NextGen announced favorable survey results, conducted by the Harris Poll, on patients availing telehealth services. The survey results reflect that more than half of the U.S. patient population has stated that the pandemic has significantly changed the way they would like to communicate with their doctors.
Also in May, the company announced the implementation of Application Programming Interface (“API”) technology to support the COVID-19 vaccine administration programs in California. NextGen is working with California’s Third-Party Administrator, Blue Shield, and has developed a high-fidelity connection between California’s My Turn program and EHRs in clinics across the state.
Price Performance
Shares of the Zacks Rank #4 (Sell) company have gained 56.6% in the past year compared with the industry’s growth of 4.7%.
Stocks to Consider
Some better-ranked stocks from the broader medical space are Veeva Systems Inc. (VEEV - Free Report) , DaVita Inc. (DVA - Free Report) and Encompass Health Corporation (EHC - Free Report) , each currently carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Veeva Systems’ long-term earnings growth rate is estimated at 15.8%.
DaVita’s long-term earnings growth rate is estimated at 14.4%.
Encompass Health’s long-term earnings growth rate is projected at 17.3%.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
NextGen Healthcare, Inc. recently announced that Pametto Retina Center (“Palmetto”) has adopted NextGen Revenue Cycle Management (RCM) Services. Palmetto, which is currently using NextGen Enterprise Practice Management (PM) and NextGen Enterprise electronic health record (EHR), has adopted NextGen RCM Services for six locations in South Carolina. With the addition of NextGen RCM Services, Palmetto will reap the benefits of the integrated platform backed by expert managed services focused on boosting cashflow while lowering administrative burden.
Notably, NextGen RCM Services aids practices in preventing denials, enhance speed of collections, increase net collections, and lower days in accounts receivable, thereby improving overall patient experience.
NextGen is a major player in the U.S. RCM market and this announcement is likely to strengthen its position further in the same.
More on the News
For a healthy and smooth flowing retina practice, timely reimbursement for medications and surgeries is crucial. On the back of the expansion of Palmetto’s collaboration with NextGen, the former will be able to receive an end-to-end solution for its team.
Per management, with the continued evolution of the market, there is a higher demand for the combination of well-integrated clinical and financial workflows coupled with managed services.
This partnership will allow NextGen to cater to the needs of the changing healthcare environment and enhance Palmetto’s financial strength.
Market Prospects
Per a report by Grand View Research, the global revenue cycle management market was worth $261.8 billion in 2020 and is projected to witness a CAGR of 11.5% from 2021 to 2028. Growing need for optimization of organizational workflow, and increase in innovation in synchronized management software and systems are expected to drive market growth. Hence, the announcement is well-timed for NextGen.
Recent Developments
In May, NextGen announced favorable survey results, conducted by the Harris Poll, on patients availing telehealth services. The survey results reflect that more than half of the U.S. patient population has stated that the pandemic has significantly changed the way they would like to communicate with their doctors.
Also in May, the company announced the implementation of Application Programming Interface (“API”) technology to support the COVID-19 vaccine administration programs in California. NextGen is working with California’s Third-Party Administrator, Blue Shield, and has developed a high-fidelity connection between California’s My Turn program and EHRs in clinics across the state.
Price Performance
Shares of the Zacks Rank #4 (Sell) company have gained 56.6% in the past year compared with the industry’s growth of 4.7%.
Stocks to Consider
Some better-ranked stocks from the broader medical space are Veeva Systems Inc. (VEEV - Free Report) , DaVita Inc. (DVA - Free Report) and Encompass Health Corporation (EHC - Free Report) , each currently carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Veeva Systems’ long-term earnings growth rate is estimated at 15.8%.
DaVita’s long-term earnings growth rate is estimated at 14.4%.
Encompass Health’s long-term earnings growth rate is projected at 17.3%.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on DVA - FREE
Get the latest research report on VEEV - FREE
Get the latest research report on EHC - FREE